Remove Biopharma Remove Leads Remove Patients Remove Pharmaceutical products
article thumbnail

Pfizer secures rights for RSV therapeutic candidate sisunatovir in China

Pharmaceutical Technology

The deal is pursuant to the existing strategic collaboration of the companies for expanding patient access to new therapeutics in Greater China. Now, Pfizer will lead all the development, commercialisation activities as well as costs for the RSV therapeutic candidate in the regions.

article thumbnail

Getting ahead of regulatory changes around PFAS in pharmaceutical packaging

Clarivate

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] The food sector has already initiated the publication of preliminary regulations aimed at restricting PFAS in packaging. [3].

article thumbnail

Practical advice for Early Scientific Advice (ESA) in HTA submissions

pharmaphorum

In recent years, the biopharma market has become progressively complex. As a result, payers are feeling increased pressure to make the right decisions based on the perceived value of each product. HTA agencies can assist biopharma companies at the early stages of development to ensure they are meeting the expectations of payers.